# Study of Drug 1 (Enzalutamide) Plus Drug 2 (Relacorilant) for Patients With Prostate Cancer

> **NCT03674814** · PHASE1 · COMPLETED · sponsor: **University of Chicago** · enrollment: 42 (actual)

## Conditions studied

- Prostate Cancer

## Interventions

- **DRUG:** Enzalutamide
- **DRUG:** Relacorilant

## Key facts

- **NCT ID:** NCT03674814
- **Lead sponsor:** University of Chicago
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-10-23
- **Primary completion:** 2024-06-10
- **Final completion:** 2024-06-10
- **Target enrollment:** 42 (ACTUAL)
- **Last updated:** 2026-03-31

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03674814

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03674814, "Study of Drug 1 (Enzalutamide) Plus Drug 2 (Relacorilant) for Patients With Prostate Cancer". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT03674814. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*